Sahar Ravanshad; Zahra Fahimian; Parsa Shoghi; Ali Moradi; Valareza Alizadeh; Negar Javdan; Hassan Mehrad-Majd
Abstract
Introduction: Studying the survival factors of leukemia patients can lead to a reduction in healthcare costs. This study aimed to evaluate the survival rate and potential predictive factors in leukemia patients in northeast Iran.Methods: Baseline demographic and clinical data of patients referred to ...
Read More
Introduction: Studying the survival factors of leukemia patients can lead to a reduction in healthcare costs. This study aimed to evaluate the survival rate and potential predictive factors in leukemia patients in northeast Iran.Methods: Baseline demographic and clinical data of patients referred to Ghaem Hospital between 2014 and 2019 were extracted from their medical records. The survival rates were determined by gathering information from phone calls or archived files.Results: This cohort study consisted of 302 patients with a mean age of 41.09±19.09 years. Among them, 127 (43.3%) had acute lymphoid leukemia, while 166 (56.7%) had myeloid leukemia. The mean overall survival time for all patients was 50.81 months. However, the mean overall survival time for patients with lymphoid leukemia (61.7 months) was significantly higher (P<0.001) than that for patients with myeloid leukemia (41.1 months). Moreover, lymphoid patients had significantly higher one-month and one-year survival rates (93% and 72.8%) than the myeloid group (81% and 53.7%) (P=0.002 and P=0.001). However, significant difference did not exist in the five-year survival rate between the lymphoid and myeloid groups (26.2% vs 18.2%, P=0.174). Cox regression analysis indicated that patient survival was correlated with the type of leukemia (1.45, 95%CI=1.10-8.92, P=0.011), age, hemoglobin levels, as well as WBC, RBC, neutrophil, and platelet count.Conclusion:Our findings indicated that patients with lymphoid leukemia exhibited a higher survival rate than those with myeloid leukemia. Survival outcomes were dependent on patient’s age, leukemia type, and levels of WBC, RBC, neutrophil, platelet, and hemoglobin levels.
Kazem Anvari; Azam Anvari; Mehdi Silanian Toosi
Abstract
Esophageal squamous cell carcinoma (ESCC) is one of the most frequent malignancies, worldwide. It is important to find out what prognostic factors can facilitate diagnosis, optimize therapeutic decisions, and improve the survival of these patients. Despite improvements in surgical techniques combined ...
Read More
Esophageal squamous cell carcinoma (ESCC) is one of the most frequent malignancies, worldwide. It is important to find out what prognostic factors can facilitate diagnosis, optimize therapeutic decisions, and improve the survival of these patients. Despite improvements in surgical techniques combined with chemotherapy and/or radiotherapy, the novel therapies such as small molecule inhibitors of tyrosine kinases (TKIs) and humanized monoclonal antibodies (mAbs) are very much needed. On the other hand, neoadjuvant chemotherapy which may improve the outcome is accompanied by toxicity by destruction of normal cells. Side effects may be avoided by developing therapies that specifically target molecular characteristics of tumors. Epidermal growth factor receptor (EGFR) is one of tyrosine kinases receptors widely distributed in human epithelial cell membrane. Genetic polymorphisms in EGFR genes influence cell cycle progression, angiogenesis, apoptosis and metastasis. EGFR mutations are mostly observed in lung tumors; curiously they are more prevalent in Asian women diagnosed with adenocarcinoma. Also, esophageal SCC shows a relatively high incidence of EGFR (33%) and/or HER2 (31%) overexpression. Patients who carry these mutations in EGFR have been founded tending to have a better response to gefitinib, an EGFR-TKI, whereas patients with the wild-type genotype show a better response to conventional chemotherapy. Therefore, finding clinical characteristics and environmental interactions with EGFR can affect on investigations about novel anti-cancer therapies like monoclonal antibodies and gene therapy and studies which identify patients who may benefit from EGFR targeted therapies. Hence, it may be effective on the improvement of prognosis in these patients.